NEW YORK, October 26, 2016—Kantar Health, a leading global healthcare consulting and market research firm, is proud to announce that Mike Kelly, CEO of the Americas, has been honored with the 2016 R.R. Fordyce Award by the Pharmaceutical Marketing Research Group (PMRG). In honor of industry leader Richard “Dick” Fordyce, this award is given each year to a recipient who exemplifies the principles of excellence, innovation and integrity in pharmaceutical market research.
“Mike has inspired many colleagues both within Kantar Health and beyond,” Kantar Health Global CEO Lynnette Cooke said. “He’s always willing to give of his time when mentoring colleagues, and he’s well-respected by clients and those at competitor companies, both of which often seek his advice. I’m so proud that his contributions to healthcare market research are being recognized through this prestigious award.”
Mr. Kelly has had a long career in the pharmaceutical industry, including leadership roles in engineering, marketing, market research and sales. At Kantar Health, his leadership and business acumen have been the driving force behind his success in growing the Americas business organically and via mergers and acquisitions. He is a member of Kantar Health’s Global Strategy Board, which is responsible for setting the organization’s long-term growth strategy.
“Mike has been a leader in our profession, a mentor and a pivotal player in the history of PMRG,” said Stephanie Reynders, Executive Director at PMRG. “I’m honored to present him with our organization’s most sought-after accolade, the R.R. Fordyce Award.”
R.R. Fordyce Award recipients have made an outstanding contribution to healthcare market research. In addition, they must demonstrate a pattern of leadership that is observable in the way they serve their clients and internal business partners and the way they conduct themselves among their peers and colleagues.
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 600+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. Kantar Health is part of Kantar, the data investment management division of WPP. For more information, please visit www.kantarhealth.com.